These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9750521

  • 1. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S, Hirao Y.
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [Abstract] [Full Text] [Related]

  • 2. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ.
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [Abstract] [Full Text] [Related]

  • 3. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [Abstract] [Full Text] [Related]

  • 4. [Progress of endocrine therapy for prostate cancer and results].
    Kanetake H.
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
    [Abstract] [Full Text] [Related]

  • 5. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 6. [Total androgen blockade for prostate cancer].
    Kagebayashi Y, Ozono S, Takashima K, Yoshikawa M, Hayashi Y, Kaneko Y, Maruyama Y, Hirao Y, Okajima E.
    Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
    [Abstract] [Full Text] [Related]

  • 7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 8. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Mar; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A, Kuroiwa S, Okada M, Abe F.
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 14. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF, Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Vogelzang NJ, Chodak GW, Klein EA, Schellenger JJ, Kolvenbag GJ.
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [Abstract] [Full Text] [Related]

  • 15. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T, Aizawa T, Yamamoto S, Ohkubo Y, Tsujino S, Miki M.
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [Abstract] [Full Text] [Related]

  • 16. [Hormonal therapy for prostatic cancer--state of the art].
    Miyakita H.
    Nihon Rinsho; 2005 Feb; 63(2):305-8. PubMed ID: 15714983
    [Abstract] [Full Text] [Related]

  • 17. Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate.
    Kobayashi M, Nukui A, Morita T.
    Int J Urol; 2005 Nov; 12(11):1010-1. PubMed ID: 16351663
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S, Yamazaki S, Kitamura T.
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [Abstract] [Full Text] [Related]

  • 20. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E, Scandinavian Prostatic Cancer Group-5 Trial Study.
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.